Bexson Biomedical Is Developing A Customized, Wearable Ketamine Delivery Device For Non-Opioid Pain Management

Bexson Biomedical, Inc. is developing a subcutaneous ketamine treatment platform for non-opioid, outpatient pain management. It is collaborating with Italian-based Stevanato Group, a leading producer of glass primary packaging and provider of integrated capabilities for drug delivery system. The collaboration will focus on developing a customized version of the SG EZ-be Pod®, a wearable drug delivery device, for Bexson's proprietary ketamine formulation, BB106. The two companies will work closely together to produce a small, wearable, and programmable device, leveraging Stevanato Group's experience in contract manufacturing and medical device innovation. This technology will pair with Bexson . . .